1887
Volume 2013, Issue 4
  • ISSN: 2305-7823
  • E-ISSN:

Abstract

Heart failure with preserved ejection fraction (HFpEF) continues to be a challenging form of heart failure – one in which no therapy has yet been proven to improve outcome. Aldosterone antagonists have previously been shown to improve survival in a wide spectrum of patients with heart failure with reduced ejection fraction (HFrEF), and more recently, small trials suggested that they might have role in HFpEF patients. The effect of spironolactone on clinical outcomes in HFpEF was tested in the TOPCAT study.

Loading

Article metrics loading...

/content/journals/10.5339/gcsp.2013.42
2014-01-01
2019-08-22
Loading full text...

Full text loading...

/deliver/fulltext/gcsp/2013/4/gcsp.2013.42.html?itemId=/content/journals/10.5339/gcsp.2013.42&mimeType=html&fmt=ahah

References

  1. [1]. Yusuf   S., , Pfeffer   MA., , Swedberg   K., , Granger   CB., , Held   P., , V McMurray   JJ., , Michelson   EL., , Olofsson   B., , Ostergren   J. . Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. . Lancet . Sep. 2003; ;362: 9386 : 777– 781 .
    [Google Scholar]
  2. [2]. Cleland   JGF., , Tendera   M., , Adamus   J., , Freemantle   N., , Polonski   L., , Taylor   J. . The perindopril in elderly people with chronic heart failure (PEP-CHF) study. . Eur Heart J . Oct. 2006; ;27: 19 : 2338– 2345 .
    [Google Scholar]
  3. [3]. Massie   BM., , Carson   PE., , McMurray   JJ., , Komajda   M., , McKelvie   R., , Zile   MR., , Anderson   S., , Donovan   M., , Iverson   E., , Staiger   C., , Ptaszynska   A. . Irbesartan in patients with heart failure and preserved ejection fraction. . N Engl J Med . Dec. 2008; ;359: 23 : 2456– 2467 .
    [Google Scholar]
  4. [4]. Flather   MD., , Shibata   MC., , Coats   AJS., , Van Veldhuisen   DJ., , Parkhomenko   A., , Borbola   J., , Cohen-Solal   A., , Dumitrascu   D., , Ferrari   R., , Lechat   P., , Soler-Soler   J., , Tavazzi   L., , Spinarova   L., , Toman   J., , Böhm   M., , Anker   SD., , Thompson   SG., , Poole-Wilson   PA. . Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). . Eur Heart J . Feb. 2005; ;26: 3 : 215– 225 .
    [Google Scholar]
  5. [5]. Ahmed   A., , Rich   MW., , Fleg   JL., , Zile   MR., , Young   JB., , Kitzman   DW., , Love   TE., , Aronow   WS., , Adams   KF., , Gheorghiade   M. . Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. . Circulation . Aug. 2006; ;114: 5 : 397– 403 .
    [Google Scholar]
  6. [6]. Desai   AS., , Lewis   EF., , Li   R., , Solomon   SD., , Assmann   SF., , Boineau   R., , Clausell   N., , Diaz   R., , Fleg   JL., , Gordeev   I., , McKinlay   S., , O'Meara   E., , Shaburishvili   T., , Pitt   B., , Pfeffer   MA. . Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. . Am Heart J . Dec. 2011; ;162: 6 : 966. e10– 972. e10 .
    [Google Scholar]
  7. [7]. Struthers   AD., , MacDonald   TM. . Review of aldosterone- and angiotensin II-induced target organ damage and prevention. . Cardiovasc Res . Mar. 2004; ;61: 4 : 663– 670 .
    [Google Scholar]
  8. [8]. Pitt   B., , Zannad   F., , Remme   WJ., , Cody   R., , Castaigne   A., , Perez   A., , Palensky   J., , Wittes   J. . The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. . N Engl J Med . Sep. 1999; ;341: 10 : 709– 717 .
    [Google Scholar]
  9. [9]. Pitt   B., , Williams   G., , Remme   W., , Martinez   F., , Lopez-Sendon   J., , Zannad   F., , Neaton   J., , Roniker   B., , Hurley   S., , Burns   D., , Bittman   R., , Kleiman   J. . The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. . Cardiovasc Drugs Ther . Jan. 2001; ;15: 1 : 79– 87 .
    [Google Scholar]
  10. [10]. Zannad   F., , V McMurray   JJ., , Krum   H., , van Veldhuisen   DJ., , Swedberg   K., , Shi   H., , Vincent   J., , Pocock   SJ., , Pitt   B. . Eplerenone in patients with systolic heart failure and mild symptoms. . N Engl J Med . Jan. 2011; ;364: 1 : 11– 21 .
    [Google Scholar]
  11. [11]. Mottram   PM., , Haluska   B., , Leano   R., , Cowley   D., , Stowasser   M., , Marwick   TH. . Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. . Circulation . Aug. 2004; ;110: 5 : 558– 565 .
    [Google Scholar]
  12. [12]. Daniel   KR., , Wells   G., , Stewart   K., , Moore   B., , Kitzman   DW. . Effect of aldosterone antagonism on exercise tolerance, Doppler diastolic function, and quality of life in older women with diastolic heart failure. . Congest Heart Fail . 15: 2 : 68– 74 .
    [Google Scholar]
  13. [13]. Pieske   BM. . ALDO-DHF: aldosterone receptor blockade in diastolic heart failure. . European Society of Cardiology 2012 Congress, Munich, Germany . [Online]. Available: http://www.eurekalert.org/pub_releases/2012-08/esoc-tas082612.php. [Accessed 05 Sep 2012] .
    [Google Scholar]
  14. [14]. Owan   TE., , Redfield   MM. . Epidemiology of diastolic heart failure. . Prog Cardiovasc Dis . Mar. 2005; ;47: 5 : 320– 332 .
    [Google Scholar]
  15. [15]. Bhatia   RS., , V Tu   J., , Lee   DS., , Austin   PC., , Fang   J., , Haouzi   A., , Gong   Y., , Liu   PP. . Outcome of heart failure with preserved ejection fraction in a population-based study. . N Engl J Med . Jul. 2006; ;355: 3 : 260– 269 .
    [Google Scholar]
  16. [16]. Shah   AM., , Shah   SJ., , Anand   IS., , Sweitzer   NK., , O'Meara   E., , Heitner   JF., , Sopko   G., , Li   G., , Assmann   SF., , McKinlay   SM., , Pitt   B., , Pfeffer   MA., , Solomon   SD. . Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. . Circ Heart Fail . Nov. 2013; ; , doi: 10.1161/CIRCHEARTFAILURE.113.000887 .
    [Google Scholar]
  17. [17]. Paulus   WJ., , van Ballegoij   JJM. . Treatment of heart failure with normal ejection fraction: an inconvenient truth!.   J Am Coll Cardiol . Feb. 2010; ;55: 6 : 526– 537 .
    [Google Scholar]
  18. [18]. ElGuindy   A., , Yacoub   M. . Heart failure with preserved ejection fraction. . GCSP . 2012: 10 , http://dx.doi.org/10.5339/gcsp.2012.10 .
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/gcsp.2013.42
Loading

Supplementary File 1

  • Article Type: Research Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error